Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
44 results about "Infarct volume" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Infarct volume is one of the common indexes for assessing the extent of ischemic brain injury following focal cerebral ischemia. Accuracy in the measurement of infarct volume is compounded by postischemic brain edema that may increase brain volume in the infarcted region.
GRPAK/tetrahydroglyoxaline/RGD ternary conjugate as well as preparation method and application thereof
InactiveCN102875644AExcellent scavenging activityHigh NO free radical scavenging activityPeptide/protein ingredientsAntinoxious agentsIn vivoHigh activity
The invention discloses a GRPAK / tetrahydroglyoxaline / RGD ternary conjugate as well as a preparation method and application of the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate. According to the preparation method, L-Lys is served as a link arm, and 1, 3-dioxo-2-[(4-peracetic acid) phenyl]-4, 4, 5, 5-tetramethyl tetrahydroglyoxaline, the GRPAK pentapeptide with a thrombolytic effect, and RGD tetrapeptide with an antithrombosis effect are integrally linked, thus obtaining the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate as shown in formula I. The GRPAK / tetrahydroglyoxaline / RGD ternary conjugate disclosed by the invention has high activity on removing NO free radical, excellent thrombolytic activity and antithrombosis activity; as in-vivo apoplexy activity shown, the GRPAK / tetrahydroglyoxaline / RGD ternary conjugate can effectively protect the neurologic function of a rat subjected to apoplexy, and reduces the brain infarct volume of the rat subjected to apoplexy, and has high apoplexy resisting activity, and can be prepared into a clinical medicine for treating apoplexy or cerebral infarction.
Owner:YONG GUANG PHARMA
Methods for the treatment of brain edema
InactiveUS20090286799A1Reduced infarct volumeReduce mortalityBiocideAnimal repellantsMortality rateCalcium influx
The present invention is based on the discoveries that PAN-811 (1) reduces infarct volume, suppresses brain edema and decreases mortality associated with ischemia; (2) blocks veratridine-induced swelling and neuronal cell death; (3) chelates free calcium and inhibits MMP-9 activity; and (4) blocks calcium-induced neuronal cell death and suppresses glutamate-induced calcium influx into neuronal cells. More particularly, the present invention relates to methods for treating, ameliorating or preventing vasogenic and / or cytotoxic brain edema, by administering to a subject in need thereof certain thiosemicarbazone compounds or pharmaceutically acceptable salts thereof. An example of such a thiosemicarbazone is 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (PAN-811).
Owner:PANACEA PHARMA
Thrombolysis oligopeptide-imidazolidine binary conjugate, preparation method and uses thereof
InactiveCN102898507AExcellent scavenging activityHigh NO free radical scavenging activityTetrapeptide ingredientsAntinoxious agentsIn vivoRisk stroke
The present invention discloses a thrombolysis oligopeptide-imidazolidine binary conjugate, a preparation method and uses thereof. According to the present invention, L-Lys is adopted as a linking arm to link 1,3-dioxy-2-[(4-oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline, ARPAK having a thrombolysis effect, GRPAK, RPAK or PAK to obtain the thrombolysis oligopeptide-imidazolidine binary conjugate represented by a formula I or II, wherein the thrombolysis oligopeptide-imidazolidine binary conjugate integrally has characteristics of nanometer structure, BBB crossing, thrombolysis and NO removing. The thrombolysis oligopeptide-imidazolidine binary conjugate has high NO free radical clearance activity, excellent thrombolysis activity and excellent antithrombosis activity. In vivo anti-stroke activity test results show that: with the thrombolysis oligopeptide-imidazolidine binary conjugate, nerve functions of stroke rats can be effectively protected, brain infarct volume of the stroke rats can be reduced, excellent anti-stroke activity is provided, and the thrombolysis oligopeptide-imidazolidine binary conjugate can be prepared into a clinical drug for brain infarction treatment.
Owner:SHANGHAI LUMOSA THERAPEUTICS
Nicotinic acid derivative and application thereof
ActiveCN104788440AEasy to solveGood treatment effectOrganic active ingredientsNervous disorderDiseaseTreatment effect
The invention relates to a novel nicotinic acid derivative and an application thereof and further relates to the application of the nicotinic acid derivative in preparation of medicine and pharmaceutic preparation for disease prevention or treatment, especially for prevention or treatment of stroke diseases. Experiments prove that the nicotinic acid derivative has a direct protection function on neurons on a cell model and substantially reduces the hindbrain infarct volume of a mouse with ischemic stroke in an animal model. Therefore, the application of the nicotinic acid derivative with the novel chemical structural formula in preparation of the medicine for prevention or treatment of the stroke diseases is provided. The nicotinic acid derivative contains a nicotinic acid pharmacophore as well as pharmacophores aiming at other pathogenic mechanisms, and the nicotinic acid derivative has better stroke disease prevention or / and treatment effect than the prototype drug nicotinic acid.
Owner:SUZHOU UNIV
Application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of medicament for treating ischemic stroke
InactiveCN103058975AObvious effectOrganic active ingredientsOrganic chemistryReperfusion injuryMedicine
The invention discloses an application of 5,7-dihydroxy-4'-methoxy flavone preparation extracted from snow lotus in preparation of a medicament for treating ischemic stroke. By effectively extracting the 5,7-dihydroxy-4'-methoxy flavone preparation from the snow lotus and establishing an ischemia reperfusion model of a mouse, the influence of acacetin on the infarct volume and the neurologic impairment caused by ischemia reperfusion injury of the mouse is observed. The study carried out by establishing an SH-SY5Y cell OGD model, testing the cell viability and the cell apoptosis, and demonstrating the integral level of the acacetin shows that the acacetin has the effect of significantly reducing the infarct volume, improving the neurologic function score, promoting the cell survival and reducing the cell apoptosis, clarifies that the acacetin has a neurologic protection effect on the cerebral ischemia reperfusion injury and proves that the 5,7-dihydroxy-4'-methoxy flavone preparation can be well applied to preparing the medicament for treating ischemic stroke and has wide application value.
Owner:朱沂
3H-1,2-dithio-cyclopentene-3-thioketone compound and application thereof
The invention relates to the field of medicaments, and in particular relates to a 3H-1,2-dithio-cyclopentene-3-thioketone compound and an application thereof. The 3H-1,2-dithio-cyclopentene-3-thioketone compound disclosed by the invention has a structure shown in a formula I or a formula II and is a compound with a completely-new structure. Proved by experiments, the 3H-1,2-dithio-cyclopentene-3-thioketone compound has a direct protection role on neurons on a cell model, and can obviously restrain excessive inflammatory responses of inflammatory cells in the cerebrum; and by using 3H-1,2-dithio-cyclopentene-3-thioketone, focal cerebral ischemia cerebral infarction volume of a mouse can be obviously reduced in an animal model. Therefore, the invention provides the 3H-1,2-dithio-cyclopentene-3-thioketone compound and the application of acceptable slat of the 3H-1,2-dithio-cyclopentene-3-thioketone compound on the pharmacy aspect to the preparation of medicaments for preventing or treating a cerebral apoplexy disease.
Owner:SUZHOU UNIV
Application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia
The invention provides an application of total saponins of bacopa monnieri (L.) wettst. in preparation of medicaments for resisting cerebral ischemia. The total saponins of the bacopa monnieri (L.) wettst. mainly comprise the following dammarane type triterpenoid saponin compounds: bacopaside I, bacoside A3, bacopaside II, bacopasaponin cisomer and bacopasaponin C. The invention further provides an application of the bacopaside I in preparation of a medicament for resisting cerebral ischemia. The experimental study shows that the total saponins of the bacopa monnieri (L.) wettst. and the bacopaside I have the effects of improving the behavioral symptoms caused by cerebral ischemia reperfusion injury, reducing the cerebral infarct volume and reducing the cerebral edema caused by cerebral ischemia of a rat. Therefore, the total saponins of the bacopa monnieri (L.) wettst. can be used for preparing the medicaments for preventing and treating cerebral ischemia. The medicaments for preventing and treating the cerebral ischemia are prepared from the total saponins of the bacopa monnieri (L.) wettst. or bacopaside I as the active component and medicinal accessories by adopting a conventional method. The invention further expands the function of the bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. and provides the novel medicaments for preventing and treating the cerebral ischemia. The bacopaside I and the total saponins of the bacopa monnieri (L.) wettst. have high clinical application values.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
RPAK/imidazolidine/RGD ternary conjugate, preparation method and uses thereof
InactiveCN102898506AExcellent scavenging activityHigh NO free radical scavenging activityPeptide/protein ingredientsAntinoxious agentsImidazolidineThrombus
The present invention discloses an RPAK / imidazolidine / RGD ternary conjugate, a preparation method and uses thereof. According to the present invention, L-Lys is adopted as a linking arm to link 1,3-dioxy-2-[(4-oxyacetic acid)phenyl]-4,4,5,5-tetramethylimidazoline, an RPAK tetrapeptide having a thrombolysis effect, and a RGD tetrapeptide having an anti-thrombosis effect to obtain the RPAK / imidazolidine / RGD ternary conjugate represented by a formula I, wherein the RPAK / imidazolidine / RGD ternary conjugate integrally has effects of BBB crossing, thrombolysis and NO removing. The RPAK / imidazolidine / RGD ternary conjugate has high NO free radical clearance activity, excellent thrombolysis activity and excellent anti-thrombosis activity. In vivo anti-stroke activity test results show that: with the RPAK / imidazolidine / RGD ternary conjugate, nerve functions of stroke rats can be effectively protected, brain infarct volume of the stroke rats can be reduced, anti-stroke activity is provided, and the RPAK / imidazolidine / RGD ternary conjugate can be adopted as a clinical drug for brain infarction treatment.
Owner:YONG GUANG PHARMA
Use of methylene blue in prevention of acute cerebral ischemia damage
InactiveCN104027338AImprove performanceReduced infarct volumeOrganic active ingredientsFood preparationIntraperitoneal routeModerate-Dose
The invention relates to novel use of methylene blue (MB) in prevention of acute cerebral ischemia. MB can remarkably reduce cerebral ischemia infarction caused by permanent middle cerebral artery occlusion (middle cerebral artery occlusion MCAO) and alleviate damage of neurological function. The inventors of the invention permanently occlude middle cerebral artery of a mouse by adopting a suture method and after intraperitoneal injection of MB at the moment and at different time points after cerebral ischemia, changes on degree and ethology of permanent cerebral ischemia infarction of the mouse are observed. Researches discover that MB can remarkably reduce infarct volume caused by cerebral ischemia and improve the active ability of the mouse after cerebral ischemia. Through the method provided by the invention, moderate doses of MB are delivered for many times after cerebral ischemia can remarkably alleviate damage degree after permanent cerebral ischemia of the mouse so as to improve the active ability of the mouse after cerebral ischemia. The use of MB is expected to provide a rescue therapeutic measure to cerebral apoplexy and alleviate permanent neurological function deficit after golden treatment period.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Application of cholest-4-ene-3,6-dione in preparing drug for treating or preventing neuron injury
The invention discloses an application of cholest-4-ene-3,6-dione in preparing a drug for treating or preventing neuron injury. Cholest-4-ene-3,6-dione can relieve hippocampus neuron oxidative stressinjury caused by glutamic acid, cerebellar granule neuron apoptosis injury caused by potassium deprivation and cortical neuron and cerebellar granule neuron oxidative stress injury caused by glutamicacid, also has a function of remarkably reducing infarct volume in an MACO (middle cerebral artery occlusion) model of a stroke rat and has the potential of a neuroprotective agent used for being developed into multiple acting mechanisms. Neurodegenerative diseases such as the Parkinson's disease, the Alzheimer's disease, the tau protein disease, amyotrophic lateral sclerosis and the like as wellas cerebral stroke, cerebral injury and spinal cord injury are all caused by neuron injury, and neuron injury is further aggravated. Cholest-4-ene-3,6-dione has a protection function on neuron injuryand has potential functions in drugs for treating or preventing neuron injury.
Owner:SUN YAT SEN UNIV
Edaravone composition for injection
InactiveCN103301119AGood treatment effectReduce dosePowder deliveryOrganic active ingredientsSide effectHalf-life
The invention provides an edaravone composition for injection, and relates to the technical field of medicine manufacturing. The main medicine of the composition comprises edaravone and melatonin, wherein the melatonin comprises a quick release part and a cyclodextrin-included slow release part. According to the edaravone composition for injection provided by the invention, the therapeutic effect of edaravone is improved, instability caused by oral administration of MT (Melatonin) is avoided and MT is quick to distribute and eliminate and the like, and the first pass effect of MT is reduced. The dosage of edaravone is reduced, and the side effect of edaravone is reduced. The design of dosage combining quick release and slow release is in accordance with secretion characteristic of MT, so that the problem of half-life period of MT is solved and the bioavailability of a product is improved. The melatonin combined with edaravone acted on nerve cells has the synergistic effect of preventing encephaledema, reducing the infarct volume and improving the neurological function.
Owner:HAINAN WEI KANG PHARMA QIANSHAN
Cell therapy for the treatment of neurodegeneration
ActiveUS20140219969A1Effective treatmentReduces a neurological deficitBone marrow stroma cellsBiocideArterial occlusionsBone marrow cell
Methods are described for the isolation and selection of a heterogeneous bone marrow cell population, called NCS-01, that is effective at treating neurodegeneration. For example, NCS-01 cells are shown to treat neurodegeneration caused by ischemia. In vivo studies demonstrate that selected NCS-01 cell populations treat neurodegeneration in a standard rat middle cerebral artery occlusion (MCAO) animal model under conditions of transient or permanent total arterial occlusion. These studies also disclose that when the neurodegeneration is caused by ischemic stroke, combining the administration of a selected NCS-01 cell population with thrombolytic agents and / or mechanical methods of clot removal leads to a decrease in the volume of infarction caused by acute onset neurodegeneration. The disclosed cell therapy promises to make a significant clinical impact on patient survival after stroke.
Owner:NC MEDICAL RES
Application of (Z)-2-imino-5-(3,5-dimethoxyphenylmethylene)-1-methylimidazolidinyl-4-one in preparation of cardiovascular drugs
ActiveCN104983731ASignificant cardioprotective effectOrganic active ingredientsCardiovascular disorder1-MethylimidazoleIschemic cardiomyopathy
The invention discloses an application of (Z)-2-imino-5-(3,5-dimethoxyphenylmethylene)-1-methylimidazolidinyl-4-one in the preparation of cardiovascular drugs. Specifically, the provided compound has a prominent effect on reducing damage caused by myocardial ischemia / reperfusion; is capable of prominently reducing the infarct volume in left ventricle of myocardial ischemia rats, and is suitable for preparing drugs for preventing and / or treating cardiovascular diseases especially ischemic cardiomyopathy, myocardial ischemia / reperfusion damage, and the like.
Owner:SUZHOU UNIV
Nerve injury resisting method of ischemic brain injury animal model
The invention discloses a nerve injury resisting method of an ischemic brain injury animal model. The nerve injury resisting method comprises the following steps of S1, establishing the ischemic braininjury animal model; S2, performing lumbricusion administration experiment; S3, performing behavioristics testing, measuring infarct volume, and observing the influence of the lumbricusion on the expression of VEGF (vascular endothelial growth factor) and CD34 related with ischemic penumbra and angiogenesis of an ischemic brain injury mouse; observing the influence of the lumbricusion on the protein expression of related VEGF, PI3K (phosphatidyl inositol-3-kinase) and AKT (protein kinase B) factors of the PI3K-AKT signal channels of a local ischemic brain injury mouse. The nerve injury resisting method has the advantages that according to the animal experiment, the optimum dosage of the lumbricusion for realizing the nerve protection effect on the ischemic brain injury animal is determined; according to the reliable testing indexes, the lumbricusion can be used for performing nerve protection on the ischemic brain injury.
Owner:LANZHOU UNIVERSITY
Purposes of piperlongumine used for preparing medicine preventing cerebral arterial thrombosis
ActiveCN105106202ASmall side effectsHigh clinical application valueOrganic active ingredientsCardiovascular disorderReperfusion injuryCerebral arterial thrombosis
The invention relates to the medical technology field, and provides purposes of piperlongumine used for preparing a medicine preventing cerebral arterial thrombosis. Through pharmacological test of a mouse focal cerebral ischemia model, the facts are discovered that piperlongumine can improve behavior symptoms caused by mouse cerebral ischemia reperfusion injury obviously, the cerebral infarction size is reduced, and encephaledema degree of a mouse with cerebral ischemia is lowered. Thus piperlongumine can be used for preparing a medicine preventing cerebral arterial thrombosis.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Polyphenol derivative compound 6-CEPN as therapeutic agent for acute ischemic stroke
A novel flavonoid derivative compound 6-CEPN can protect a brain against ischemia / reperfusion (I / R) injury by attenuating peroxynitrite-mediated mitochondrial autophagy. The infarct volume and neurological impairment score of acute ischemic stroke is significantly improved by 6-CEPN. It is found that the 6-CEPN inhibites excess mitochondrial autophagy activation during brain I / R injury, accompanied by a reduction in the production of peroxynitrite. Specifically, the 6-CEPN inhibites the expression ratio of LC3-II / I and Drp1 in the mitochondrial fraction in a dose-dependent manner, as well as the protein expression of the iNOS and NADPPH oxidase subunit p47phox.
Owner:THE UNIVERSITY OF HONG KONG
Methods of treating brain ischemia or hypoxia
InactiveUS20160199393A1Improve and even treat ischemic brain damageReduced infarct volumeBiocideNervous disorderCysteine thiolateExcitotoxicity
Methods of treating brain ischema or hypoxia by using an inhibitor of cysteine-glutamate transporter (i.e. system xc−) is provided. The inhibitor includes sorafenib and a derivative thereof, erastin, and suifasalazine. These inhibitors can effectively decrease a concentration of extracellular glutamate, so that excitotoxicity to central nervous system (CNS) and a cortical infarct volume in brains can be reduced.
Owner:CHINA MEDICAL UNIVERSITY(TW)
GAMBOGIC AMINE, A SELECTIVE TrkA AGONIST WITH NEUROPROTECTIVE ACTIVITY
InactiveUS20110077293A1Reduced infarct volumePotent neurotrophic activityBiocideNervous disorderNeuron cell deathGambogic acid
Small molecule agonists, partial agonists, and antagonists for the TrkA receptor are described. The compounds are gambogic amines, where the carboxylic acid group of gambogic acid (CO2H) has been replaced by an amine group (CH2NR1R2). In some embodiments, the compounds selectively bind to TrkA but not TrkB or C, robustly induce its tyrosine phosphorylation and downstream signaling activation including Akt and MAP kinases. Further, they can strongly prevent glutamate-induced neuronal cell death and provoke prominent neurite outgrowth in PC12 cells. Gambogic amines specifically interact with the cytoplasmic juxtamembrane domain of TrkA receptor and trigger its dimerization. Administration of these compounds in can substantially diminishes Kainic acid-triggered neuronal cell death and decrease infarct volume in transient middle cerebral artery occlusion (MCAO) model of stroke. Thus, these compounds can provide effective treatments for debilitating neurodegenerative diseases and provide neuroprotection from patients suffering from stroke or other ischemic events.
Owner:EMORY UNIVERSITY
Application of (z)-2-imino-5-(3,5-dimethoxybenzyl)-1-methylimidazolidine-4-one in the preparation of cardiovascular drugs
ActiveCN104983731BSignificant cardioprotective effectOrganic active ingredientsCardiovascular disorderReperfusion injury1-Methylimidazole
Owner:SUZHOU UNIV
Catalpol nasal drops as well as preparation method and application thereof
ActiveCN114344252AStorage properties are stableFast absorptionOrganic active ingredientsNervous disorderNasal passagesApoptosis
The invention discloses catalpol nasal drops and a preparation method and application thereof.The catalpol nasal drops are prepared from catalpol, a thickening agent, an absorption enhancer and a pH regulator, the catalpol, the thickening agent and the absorption enhancer are 10 mg / ml, the mass percentage of the thickening agent is 0.1%, the volume percentage of the absorption enhancer is 2.0%, and the pH value is 6.5-7.0; the preparation is stable in storage property under normal-temperature and dark conditions; the absorption is fast through nasal administration, the concentration in brain tissues is obviously higher than that of intravenous administration, and brain targeting is achieved; compared with oral administration and injection administration, the catalpol nasal administration dosage form can also reduce the infarct volume of brain tissues of acute cerebral ischemia patients, and can reduce the number of apoptosis of neuronal cells in a cortical region caused by cerebral ischemia injury, which shows that the catalpol nasal administration dosage form has a remarkable neuroprotective effect on the cerebral cortical region; the catalpol nasal drops have low toxicity to cilia, no obvious nasal cavity irritation is found, and the nasal administration safety is good.
Owner:SOUTHWEST UNIVERSITY
Use of smilamide for preparing medicine for preventing and treating ischemic stroke
The invention relates to the technical field of medicine, and the invention provides the use of smilaxamide for preparing a medicine for preventing and treating ischemic stroke. According to the pharmacological test of the focal cerebral ischemia model in mice, the present invention finds that smilaxamide can significantly improve the behavioral symptoms caused by cerebral ischemia-reperfusion injury in mice, reduce the volume of cerebral infarction, and reduce cerebral edema in mice with cerebral ischemia degree. Therefore, smilaxamide can be used to prepare medicines for preventing and treating ischemic stroke.
Owner:SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
Use Of (+)-2-Borneol In Preparation Of Drug For Promoting Upregulation Of Expression Of Sphingosine Kinase-1 And/Or BDNF
InactiveUS20200261375A1High expressionPromote axon growthNervous disorderHydroxy compound active ingredientsTherapeutic effectNeuron survival
Disclosed is the use of (+)-2-borneol in the preparation of a drug for promoting the upregulation of the expression of sphingosine kinase-1 and / or BDNF (a brain-derived neurotrophic factor). Herein, (+)-2-borneol can be used to prepare a drug for promoting the upregulation of the expression of the sphingosine kinase-1 and / or the brain-derived neurotrophic factor. The drug can induce astrocyte spreading and migration, oligodendrocyte differentiation and survival, and neurite growth and nerve regeneration, and can promote the upregulation of the expression of the brain-derived neurotrophic factor, promote the survival of neurons and the growth of axons, inhibit the expansion of the infarct volume, and achieve the effect of repairing damage at the site of an immediate injury while preventing further expansion of the infarct area to completely treat brain damage, so that the long-term therapeutic effect thereof is significantly improved.
Owner:SUZHOU PHARMAVAN CANCER RES CENT CO LTD
A kind of making method of the thread plug that mouse mcao model is used
InactiveCN104887340BSame sizeModerate hardness and elasticitySurgeryPharmaceutical containersPolyvinyl alcoholMortality rate
Owner:THE FIRST AFFILIATED HOSPITAL OF HENAN UNIV OF SCI & TECH
Pharmaceutical composition for treating ischemic cerebrovascular diseases and preparation method and applications thereof
InactiveCN102512562BReduce formationReduce volumeBlood disorderCardiovascular disorderDiseaseThrombus
Owner:CHENGDU UNIV OF TRADITIONAL CHINESE MEDICINE
A kind of naphthaleneacetamide compound
ActiveCN105732453BReduce volumeGood effectOrganic active ingredientsNervous disorderDiseaseCerebrovascular disorder
Owner:河北久鹏制药有限公司
Naphthalene acetamide compound
ActiveCN105732453AReduce volumeGood effectOrganic active ingredientsNervous disorderHalf-lifePotassium
The invention relates to a new naphthalene acetamide compound as shown in formula I and the salt of the naphthalene acetamide compound.Experiments prove that the naphthalene acetamide compound can be used for treating and preventing cerebral ischemic disease and improving sleep.When R=H, the naphthalene acetamide compound can react with alkali metal such as sodium, magnesium, potassium and calcium and tromethamine, diethylamine, triethylamine and the like to generate the salt which is capable of treating and preventing the cerebral ischemic disease and improving the sleep. The influence of the naphthalene acetamide compound on ischemic cerebral infarction volume is larger than that of a control group, the blood concentration of the naphthalene acetamide compound in brain tissue is higher than that of the control group, and the half-life period is prolonged evidently.
Owner:河北久鹏制药有限公司
Pharmaceutical Composition or Health Food Comprising Lonicera Coerulea Var. Edulis Fruit Extracts as Active Ingredients for Preventing or Improving Ischemic Cerebrovascular Diseases
The present invention relates to a composition containing a fruit extract of Lonicera caerulea L. var. edulis as an active ingredient for the prevention and treatment of ischemic cerebrovascular disease. The fruit extract of Lonicera caerulea L. var. edulis according to the present invention has a nerve cell-protecting effect, thereby remarkably reducing neurobehavioral impairments and infarct volume due to ischemic cerebrovascular disease. Therefore, it can be provided as a pharmaceutical composition for the prevention or treatment of ischemic cerebrovascular disease, and as a health food for the prevention or improvement of ischemic cerebrovascular disease.
Owner:UNIV IND COOP GRP OF KYUNG HEE UNIV
Treatment and prevention of stroke and other neurological disorders
ActiveUS10220008B2Effective protectionNo loss of efficacyPharmaceutical delivery mechanismBiological testingDiseaseNervous system
Using high-throughput screening, in an oxygen-glucose deprivation (OGD) model, isoxsuprine hydrochloride was identified as a potent neuroprotective compound. In an animal middle artery occlusion (MCAO) model of transient focal ischemia, isoxsuprine significantly reduced infarct volume compared to vehicle. The invention, therefore, provides methods of treatment and pharmaceutical compositions that are useful in the treatment and prevention of a wide-variety of ischemia-related injuries, including stroke.
Owner:STC UNM
Neuroprotective effect of solubilized UDCA in focal ischemic model
InactiveCN101035541BIncrease reaction strengthLow toxicityOrganic active ingredientsNervous disorderBlood flowCerebral blood flow
Owner:柳署弘
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com